Compile Data Set for Download or QSAR
maximum 50k data
Found 35 Enz. Inhib. hit(s) with all data for entry = 3223
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350340((S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)-7-chloro...)
Affinity DataIC50: <1.26nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350339((S)-3-(1-((1-acryloylpyrrolidin-3-yl)amino)-8-fluo...)
Affinity DataIC50: <1.26nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350343((S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)-8-chloro...)
Affinity DataIC50: <1.26nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350338((S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)-8-fluoro...)
Affinity DataIC50: <1.26nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350321((S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinol...)
Affinity DataIC50: <2nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350342((S)-3-(1-((1-acryloylpyrrolidin-3-yl)amino)-7-chlo...)
Affinity DataIC50: <2.51nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350341((S)-3-(1-((1-acryloylpyrrolidin-3-yl)amino)-7-fluo...)
Affinity DataIC50: <2.51nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350324((S)-3-(1-((1-acryloylpyrrolidin-3-yl)amino)isoquin...)
Affinity DataIC50: <2.51nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350344((S)-3-(1-((1-acryloylpyrrolidin-3-yl)amino)-8-chlo...)
Affinity DataIC50: <2.51nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350345((S)-3-(1-((1-acryloylpyrrolidin-3-yl)amino)-8-meth...)
Affinity DataIC50: <2.51nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350346((S)-3-(6-((1-acryloylpyrrolidin-3-yl)oxy)-4-methyl...)
Affinity DataIC50: <2.51nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350333((S)-3-(8-((1-acryloylpyrrolidin-3-yl)amino)-1,7-na...)
Affinity DataIC50: <2.51nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350336(3-(1-(((3R,4S)-1-acryloyl-4-methylpyrrolidin-3-yl)...)
Affinity DataIC50: <2.51nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350350((S)-5-(1-((1-(2-chloroacetyl)pyrrolidin-3-yl)amino...)
Affinity DataIC50: <2.51nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350332((S)-3-(8-((1-acryloylpyrrolidin-3-yl)oxy)-1,7-naph...)
Affinity DataIC50: <3.16nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350327((S)-3-(1-((1-acryloylpyrrolidin-3-yl)(methyl)amino...)
Affinity DataIC50:  3.16nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350348((S)-3-(6-((1-acryloylpyrrolidin-3-yl)oxy)-5-methyl...)
Affinity DataIC50:  5.01nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350335(3-(1-(((3R,4S)-1-acryloyl-4-methylpyrrolidin-3-yl)...)
Affinity DataIC50: <6.31nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350330((S,E)-5-(1-((1-(4-(dimethylamino)but-2-enoyl)pyrro...)
Affinity DataIC50:  6.31nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350334((S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)-7-fluoro...)
Affinity DataIC50: <6.31nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350349((S)-5-(1-((1-(2-chloroacetyl)pyrrolidin-3-yl)oxy)i...)
Affinity DataIC50: <6.31nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350320(N-(1-(3-(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)i...)
Affinity DataIC50: <7.94nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350329((S)-3-(1-(((1-acryloylpyrrolidin-3-yl)oxy)methyl)i...)
Affinity DataIC50: <10nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350322((S)-3-(1-(((1-acryloylpyrrolidin-2-yl)methyl)amino...)
Affinity DataIC50:  10nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350323((S)-3-(1-((1-acryloylpyrrolidin-2-yl)methoxy)isoqu...)
Affinity DataIC50:  10nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350325((R)-3-(1-((1-acryloylpyrrolidin-2-yl)methoxy)isoqu...)
Affinity DataIC50: <12.6nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350331((S,E)-3-(1-((1-(but-2-enoyl)pyrrolidin-3-yl)amino)...)
Affinity DataIC50:  25.1nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350351((S)-5-(1-((1-acryloylpiperidin-3-yl)oxy)isoquinoli...)
Affinity DataIC50:  31.6nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350326((S)-3-(1-((1-methacryloylpyrrolidin-3-yl)amino)iso...)
Affinity DataIC50:  31.6nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350347((S)-3-(6-((1-acryloylpyrrolidin-3-yl)oxy)pyridin-2...)
Affinity DataIC50:  63.1nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350318((R)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinol...)
Affinity DataIC50:  79.4nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350335(3-(1-(((3R,4S)-1-acryloyl-4-methylpyrrolidin-3-yl)...)
Affinity DataIC50:  126nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350328((S)-3-(1-((1-methacryloylpyrrolidin-3-yl)oxy)isoqu...)
Affinity DataIC50:  126nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350317((R)-3-(1-((1-methacryloylpyrrolidin-3-yl)oxy)isoqu...)
Affinity DataIC50:  200nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350319((R,E)-3-(1-((1-(but-2-enoyl)pyrrolidin-3-yl)oxy)is...)
Affinity DataIC50:  316nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent